Clearstead Advisors’s Definium Therapeutics DFTX Stock Holding History

Clearstead Advisors’s Portfolio DFTX Stock Details DFTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.21K	Buy	32 +18	+129%	+$759	﹤0.01%	2617
2026 Q2	$660	Buy	+14	New	+$346	﹤0.01%	2838
2022 Q4	–	Sell	-10	Closed	–	–	1353
2022 Q3	$0	Hold	10	–	–	﹤0.01%	1318
2022 Q2	$0	Sell	10 -284	-97%	-$3.59K	﹤0.01%	1379
2022 Q1	$5K	Hold	294	–	–	﹤0.01%	1079
2021 Q4	$6K	Buy	294 +84	+40%	+$2.68K	﹤0.01%	979
2021 Q3	$8K	Buy	210 +10	+5%	+$432	﹤0.01%	974
2021 Q2	$10K	Buy	+200	New	+$10.5K	﹤0.01%	799

Other funds holding DFTX

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return

AssetMark Inc Concord, California $59.5B AUM 15.92% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

Royce & Associates New York $11B AUM 39.4% 1-Year Est. Return

SEB Asset Management Stockholm $27B AUM

Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 24.61% 1-Year Est. Return

Clearstead Advisors's DFTX Position: Q3 2026 in Review

Clearstead Advisors increased its Definium Therapeutics (DFTX) stake by 129% in Q3 2026, buying an estimated $759 and bringing the position to 32 shares worth $1.21K. The position accounts for ﹤0.01% of the portfolio, ranked #2617.

Clearstead Advisors first reported a position in DFTX in Q2 2021 and has held it in 8 quarters since. The position peaked at $10K in Q2 2021. 140 funds tracked by Wall St. Rank hold DFTX as of Q3 2026.

Clearstead Advisors held 32 shares of Definium Therapeutics worth $1.21K as of Q3 2026.
Clearstead Advisors bought 18 Definium Therapeutics shares in Q3 2026, an estimated $759.
Definium Therapeutics made up ﹤0.01% of Clearstead Advisors's portfolio in Q3 2026, its #2617 holding.
Clearstead Advisors first reported a position in Definium Therapeutics in Q2 2021 and has held it in 8 quarters since.
Clearstead Advisors's Definium Therapeutics position peaked at $10K in Q2 2021.
140 funds tracked by Wall St. Rank held Definium Therapeutics as of Q3 2026.

Based on Clearstead Advisors's 13F filing for Q3 2026, filed 6 Nov 2026.